Please contact our sales representative to learn more information about this reagents.
Background
Emactuzumab (RG-7155) is a humanized monoclonal antibody directed against CSF-1R expressed on macrophages and has demonstrated a profound antitumor effect through interference with the CSF-1/CSF-1R axis, along with a manageable safety profile in patients with diffuse-type tenosynovial giant cell tumors (d-TGCT)